Article Sidebar

PDF
Date Published: 21/04/2022
Abstract Views: 982
Views PDF: 270
DOI: https://doi.org/10.51298/vmj.v511i2.2145
Issue
Vol. 511 No. 2 (2022)
Section
Các bài báo
How to Cite
Kim Thư, N. ., Bá Hiền, P. ., & Xuân Toản, L. . (2022). ASSESSMENT OF THE TREATMENT EFFICACITY OF TDF+3TC+DTG ARV REGIME IN HIV/AIDS PATIENTS AT DONG DA GENERAL HOSPITAL IN 2020-2021. Vietnam Medical Journal, 511(2). https://doi.org/10.51298/vmj.v511i2.2145

ASSESSMENT OF THE TREATMENT EFFICACITY OF TDF+3TC+DTG ARV REGIME IN HIV/AIDS PATIENTS AT DONG DA GENERAL HOSPITAL IN 2020-2021

Nguyễn Kim Thư1,, Phạm Bá Hiền2, Lê Xuân Toản2
1 Hanoi Medical University
2 Dong Da General Hospital

Main Article Content

Abstract

HIV/AIDs infection is a burden of disease for patients and their families and society as a whole. Anti-retroviral drugs (ARV) are the optimal treatment for HIV/AIDS patients. The TDF+3TC+DTG regimen was newly approved and recommended by MOH in Vietnam. Objective: To study the effectiveness and side effects of TDF + 3TC + DTG regimen in HIV/AIDS patients at Dong Da General Hospital.  Subjects: The study involved 61 patients diagnosed with HIV/AIDS and treated with the TDF+3TC+DTG regimen followed for a full 24 weeks, between February 202 and June 2021. Method: retrospective cross-description study. Results: Weight, BMI and CD4 count increases statistically (p<0.05) at the time after 24 weeks of treatment. 45/61 (73.8%) of patients reached the under detective threshold virus level. Adherence to treatment is associated with  viral load treatment result (OR=2.32 CI95% 0.21-8.643, p<0.05).  Conclusion: The TDF+3TC+DTG ARV drug regimen has a good treatment effect in patients with HIV/AIDS (weight, CD4 increases after 24 weeks of treatment and the virus is inhibited at a high rate). The group of patients who adhered to good treatment had a maximum of 2.32 times the ability to suppress the virus with a group that adhered to bad treatment.

Article Details

Keywords

HIV/AIDS, ARV, Dolutegravir

References

1. UNAIDS, “Global HIV & AIDS statistics - 2019 fact sheet”. Available at: Cục Phòng chống HIV/AIDS. Báo cáo công tác phòng, chống HIV/AIDS năm 2019 và nhiệm vụ trọng tâm năm 2020, ban hành kèm theo Quyết định số 45/BC - BYT. 2019.
2. Bộ y tế. Hướng dẫn điều trị và chăm sóc HIV/AIDS, ban hành kèm theo Quyết định 5456/QĐ-BYT ngày 20/11/2019. 2019.
3. Cục phòng chống HIV/AIDS, Hướng dẫn theo dõi phản ứng có hại của thuốc kháng HIV (ARV) trong chương trình phòng chống HIV/AIDS, ban hành kèm theo quyết định số 107/QĐ-AIDS ngày 18/06/2014. 2014.
4. Aboud M, et al. Superior efficacy of dolutegravir (DTG) plus 2 nucleoside reverse transcriptase inhibitors (NRTIs) compared with lopinavir/ritonavir (LPV/RTV) plus 2 NRTIs in second-line treatment: interim data from the DAWNING study, abstract TUAB0105LB, presented at IAS Science, 24-26 July 2017, Paris, France.
5. Taha H., Das A., và Das S. Clinical effectiveness of dolutegravir in the treatment of HIV/AIDS. Infect Drug Resist, 2015;8, 339–352.
6. Castagna A, et al. Dolutegravir in antiretroviral- experienced patients with raltegravir- and/or elvitegravir - resistant HIV-1: 24-week results of the phase III VIKING-3 study, The Journal of Infectious Diseases, August 2014.
7. Nyaku A.N., Zheng L., Gulick R.M., et al. Dolutegravir plus lamivudine for initial treatment of HIV-1-infected participants with HIV-1 RNA <500 000 copies/mL: week 48 outcomes from ACTG 5353. J Antimicrob Chemother, 2019;74(5), 1376–1380.
8. Cahn P., Madero J.S., Arribas J.R., et al. Dolutegravir plus lamivudine versus dolutegravir plus tenofovir disoproxil fumarate and emtricitabine in antiretroviral-naive adults with HIV-1 infection (GEMINI-1 and GEMINI-2): week 48 results from two multicentre, double-blind, randomised, non-inferiority, phase 3 trials. The Lancet, 2013; 393(10167), 143–155.